glp 1 receptor agonists for type 2 diabetes GLP-1 are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1 Receptor Agonists for Type

A rearranged Amaranthus palmeri extrachromosomal circular DNA confers resistance to glyphosate and glufosinate

Development and preliminary validation of a brief broad-spectrum measure of trauma exposure: the Traumatic Life Events Questionnaire

Nonetheless, these findings underscore the intricate and bidirectional relationship between metabolism and immune regulation and highlight steroid hormones as key modulators of immunometabolic activity across multiple immune cell types ( Figure 1 )

BPC-157 (Body Protection Compound 157) is a 15-amino acid peptide fragment derived from the gastric protein BPC

Semaglutide, tirzepatide, and the investigational triple agonist retatrutide all produce remarkable weight loss but clinical trial data shows that a significant fraction of that loss is lean body mass, not fat